Be part of the future

Revolutionary Heart Valve Replacement Solutions

Heart Biotech specialises in tissue engineering of heart valves, providing advanced fully functional heart valve scaffolds for heart valve replacement surgeries.

Meet Our Visionary Founders

Sir Magdi Yacoub is a professor of Cardiothoracic Surgery at Imperial College London. He founded the Magdi Yacoub Institute at Harefield Heart Science Centre and established the world’s largest heart and lung transplantation program. He has authored over 1,400 published papers and received prestigious honours, including a Knighthood and the Order of the Merit. His research into tissue engineering extends more than 30 years.

Prof Magdy Ishak is an experienced orthopaedic and spinal surgeon who developed graded pressure stockings to reduce the risk of DVT and pulmonary embolism in surgery. He was crucial in implementing ISO 9001 accreditation in healthcare and is a respected educator and senior judicator. Prof Ishak has worked on PPP projects with the British National Health Service and holds numerous leadership positions, including Chairman of the Egyptian Medical Society – UK.

HCCV scaffold production

Breakthrough

Innovative biotech solutions to save lives

Innovative tissue engineering
Patient-centric approach
Cutting-edge biotech solutions
Dedicated to improving patient outcomes

Our vision

A world where every cardiovascular patient, adult or child, can trust in a restorative valve implant that lives, grows and learns with them; enabling their bodies to rebuild what nature intended – providing a future free from compromise.

Our mission

Creating advanced solutions for heart disease patients
Improving patient outcomes
Pioneering new biotech solutions
Transforming the field of tissue engineering

Restoring hope

The "Living" valve Company

Our values:
Cutting-Edge Science

We leverage the latest advances in biotechnology to develop innovative solutions that are transforming the field of tissue engineering and surgical approaches.

Patient-Centric Approach

We prioritise the needs of patients, working hard to deliver a future that is free from a lifetime of medications, repeat surgeries and full life expectancy

Revolutionising heart disease treatment through pioneering biotech solutions

FAQ

Find answers to commonly asked questions

Our unique, patented heart valve scaffold enables each patient’s own body to build its own living valve from its own cells

Tissue engineering heart valves have several advantages over traditional replacement valves. They promise to be more durable and grow with the patient, reduce life-long medications and restore full life expectancy

Our heart valve scaffold is being designed first for pulmonary valve replacement surgeries. However, we are extending our proprietary platform technology to address other types of heart valve replacements.

The heart valve scaffold is gradually replaced by the patient’s own cells over the first year in the body, ultimately becoming living valves.

Tissue-engineered heart valves promise to be suitably colonised with the patient’s own tissue. The scaffold then dissolves, leaving the patient with a natural valve that their own body has produced, which will grow as they do.

You can follow our page on LinkedIn and visit our website for updates about our journey, or contact us directly. We would be happy to try and answer any questions you may have.

At Heart Biotech, we are dedicated to pushing the boundaries of what is possible in tissue engineering and biotechnology. Our team of experts have developed a proprietary platform technology that has potential to impact many clinical areas.

Yes, we are open to discussing potential investment opportunities. Please contact us using the contact form above to learn more.